JEADV clinical practice最新文献

{"title":"Efficacy and Tolerability of Brodalumab in 42 Adult Patients With Moderate to Severe Psoriasis: First French Real-Life Case Series on Hard-to-Treat Areas","authors":"Marc Perrussel,&nbsp;Bruno Sassolas","doi":"10.1002/jvc2.70069","DOIUrl":"https://doi.org/10.1002/jvc2.70069","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriatic hard-to-treat areas (scalp, palmoplantar, genital and nails) are associated with lower efficacy, treatment discontinuation and impaired quality of life. Recent biotherapies offer a new perspective for their treatment. Among them brodalumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults requiring systemic therapy. No French data are available on the effectiveness of brodalumab on hard-to-treat areas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To assess the effectiveness and safety of brodalumab in real life on psoriatic hard-to-treat areas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective multicenter study including 42 psoriasis adults which received at least one injection of brodalumab from January 2022 through May 2024 and were followed for a minimum period of 2 months after initiation. Scores were collected at baseline and between 2 and 20 months after treatment initiation: BSA (body surface area), PASI (psoriasis area severity index), PGA-G (Physician's Global Assessment of genitalia), ppPASI (Palmoplantar Psoriasis Area and Severity Index), NAPSI (Nail Psoriasis Severity Index) and PSSI (Psoriasis Scalp Severity Index). DLQI (Dermatology Life Quality Index) was calculated to assess the impact on quality of life. Tolerance and potential adverse events were reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean BSA at baseline was 16.3%; mean baseline scores: PASI 11.9; PGA-G 2.3; ppPASI 14.9; NAPSI 16.3; PSSI 20.2. 92.9% of patients had DLQI ≥ 10. All patients had hard-to-treat areas: scalp 69.0%; nail 50.0%; genital 50.0%; palmoplantar 35.7%. At the end of the follow-up, the mean scores were, respectively: PASI 0.8; PGA-G 0.3; ppPASI 1.1; NAPSI 2.2; PSSI 1.2. PASI &lt; 1 was achieved by 69.0% of patients. Adverse events were reported in 9.5% of patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Brodalumab demonstrated clinical efficacy on hard-to-treat areas in just 3 months of treatment, with a median treatment duration of 4.0 months. This important and rapid clinical efficacy was associated with an improvement in quality of life and good tolerance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"803-810"},"PeriodicalIF":0.5,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urticarial Plaques With Vesicles in a Young Hispanic Woman","authors":"Valeria Olvera-Rodríguez,&nbsp;Gerardo González-Martínez,&nbsp;Sonia Chávez-Álvarez,&nbsp;Bárbara Sáenz-Ibarra,&nbsp;Minerva Gómez-Flores,&nbsp;Jorge Ocampo-Candiani,&nbsp;Erika Alba-Rojas","doi":"10.1002/jvc2.70084","DOIUrl":"https://doi.org/10.1002/jvc2.70084","url":null,"abstract":"&lt;p&gt;A 22-year-old Hispanic woman with no prior medical history presented with a 4-month history of disseminated skin lesions. Initially, she developed pruritic papules and urticarial plaques in the perioral region, which progressively spread to the neck, chest, and upper extremities. She had been treated with intramuscular dexamethasone (8 mg) and oral loratadine (10 mg every 12 h for 2 weeks), achieving partial improvement. Physical examination revealed polycyclic and annular erythematous plaques with an urticarial appearance and scarce, small vesicles at the periphery (Figure 1). The patient denied systemic symptoms, including asthenia, arthralgia, or fever. Initial laboratory work-up showed hemoglobin 12.9 g/dL, platelets 283 × 10&lt;sup&gt;9&lt;/sup&gt;/L, white blood cells 6.0 × 10&lt;sup&gt;9&lt;/sup&gt;/L, and no proteinuria. Two skin biopsies were obtained for histopathologic (Figure 2) and immunohistochemical evaluation (Figure 3).&lt;/p&gt;&lt;p&gt;The patient was initially treated with oral prednisone (0.5 mg/kg/day), hydroxychloroquine (0.5 mg/kg/day), and topical corticosteroids. After excluding glucose-6-phosphate dehydrogenase deficiency, dapsone (50 mg daily) was initiated, resulting in significant improvement of lesions within 3 weeks. The patient met the 2019 EULAR/ACR and 2012 SLICC classification criteria for systemic lupus erythematosus (SLE). She was referred to the Rheumatology department, where no additional organ or systemic involvement was identified.&lt;/p&gt;&lt;p&gt;BSLE is a rare cutaneous complication of SLE, with an estimated incidence of 0.19% [&lt;span&gt;1, 2&lt;/span&gt;]. Similar to SLE, BSLE predominantly affects young women, often of African descent, in their second to fourth decades of life, although it can also occur in males and other races, or age groups [&lt;span&gt;1, 3&lt;/span&gt;]. Autoantibodies targeting the NC1 and NC2 domains of type VII collagen are the immunopathologic hallmark of both BSLE and epidermolysis bullosa acquisita (EBA) [&lt;span&gt;4&lt;/span&gt;]. In BSLE, these autoantibodies predominantly belong to IgG2 and IgG3 subclasses, whereas in EBA, they are primarily IgG1 and IgG4 [&lt;span&gt;4&lt;/span&gt;]. Additionally, bullous pemphigoid (BP) antigens (BP180 and BP230), laminin 5, and laminin 6 may also contribute to its pathogenesis [&lt;span&gt;5&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;By definition, the diagnosis of BSLE requires that patients fulfill the ACR classification criteria for SLE [&lt;span&gt;1, 2&lt;/span&gt;]. BSLE typically develops in patients with established SLE but can also present as the initial manifestation in 36%–40% of cases, with onset reported up to 18 years after SLE diagnosis [&lt;span&gt;1, 3&lt;/span&gt;]. Clinically, it is characterized by an acute onset of tense vesicles and bullae containing clear or hemorrhagic fluid. These lesions may arise on both inflamed and normal skin, commonly involving sun-exposed areas but occasionally appearing on nonexposed regions [&lt;span&gt;6&lt;/span&gt;]. The bullae typically evolve into erosions that heal without scarring, although residual hypopigmentation or hyperpigment","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"946-949"},"PeriodicalIF":0.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor's Picks","authors":"","doi":"10.1002/jvc2.70060","DOIUrl":"https://doi.org/10.1002/jvc2.70060","url":null,"abstract":"","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"375-377"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global ‘HS Uncovered’ Burden of Disease Survey","authors":"Georgios Kokolakis,&nbsp;Eva Vilarrasa,&nbsp;Amit Garg,&nbsp;Ivette Alarcon,&nbsp;Mei Go,&nbsp;Gillian Newbold,&nbsp;Aikaterini Mamareli,&nbsp;Craig Richardson,&nbsp;Barry M. McGrath,&nbsp;Philippe Guillem","doi":"10.1002/jvc2.70071","DOIUrl":"https://doi.org/10.1002/jvc2.70071","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hidradenitis suppurativa (HS) is a chronic, painful inflammatory skin disease. There is a need to evaluate how patients experience their disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The HS Uncovered survey was conducted to understand patient activation, the patient journey and burden of disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>HS Uncovered was a real-world, quantitative, online survey completed by adults who self-reported a diagnosis/suspected diagnosis of HS. The survey included patient-reported outcome measures (PROMs) and non-PROM-related questions and was conducted between December 2022 to March 2023 in six countries (US, UK, Germany, France, ltaly, Spain). PROMs included the Patient Activation Measure (PAM13; primary endpoint), Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment (WPAI) and Hospital Anxiety and Depression Scale (HADS) tools (Spain excluded from PROM analyses).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 656 participants were included (<i>N</i> = 505, diagnosed HS; <i>N</i> = 151, suspected HS). Of 425 diagnosed participants, 66% reported high (level 3/4) PAM13 scores. A very large (DLQI score 11–20) and extremely large (DLQI score 21–30) effect of HS on QoL was reported by 41% and 28% of participants, respectively. A very large to extremely large effect of HS on QoL (DLQI score 11–30) was reported by 67% and 73% of patients with level 3 and 4 PAM13 scores, respectively. Overall, 53% and 29% of diagnosed participants reported abnormal anxiety and depression, respectively. The percentage of work impairment due to HS in employed diagnosed participants (<i>N</i> = 302) was 52%. Of diagnosed females, 52% considered HS a concern for family planning. Overall (<i>N</i> = 656), 58% of participants considered pain relief the most important treatment feature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite participants having high activation levels, HS had a negative impact on QoL, mental health, work and activity. There is an unmet need for effective treatments that provide sustained pain reduction and improve work productivity in HS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"920-929"},"PeriodicalIF":0.5,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse Melanosis Cutis Under Immuno- and Targeted Therapy","authors":"Christiane Cussigh,&nbsp;Lara-Elena Hakim-Meibodi,&nbsp;Alexander H. Enk,&nbsp;Jessica C. Hassel","doi":"10.1002/jvc2.70050","DOIUrl":"https://doi.org/10.1002/jvc2.70050","url":null,"abstract":"<p>In patients with highly advanced melanoma, rarely a diffuse melanosis cutis (DMC) can be noticed. Even though the condition is generally harmless itself, it can have a significant impact on the patient's well-being as an obvious mark of the disease. DMC causes a grey or brown discoloration of the skin and mucous membranes. We report on a young female patient with advanced melanoma, who was diagnosed with diffuse melanosis cutis and a fast-progressing melanoma.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"877-879"},"PeriodicalIF":0.5,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70050","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Survey on Methotrexate Prescribing and Monitoring Practices in Ireland","authors":"Ji Fung Yong,&nbsp;Fei Lai,&nbsp;Claire Quigley,&nbsp;Li Jie Helena Yoo,&nbsp;Claudine Howard-James,&nbsp;Fatma Al Hosni,&nbsp;Gregg Murray,&nbsp;Anne-Marie Tobin","doi":"10.1002/jvc2.70046","DOIUrl":"https://doi.org/10.1002/jvc2.70046","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Methotrexate, originally an anti-neoplastic agent, is now extensively used at lower doses in dermatology and rheumatology for chronic inflammatory conditions. While its safety is supported by routine blood monitoring, there remains variability in recommended monitoring frequency, folic acid supplementation, liver function testing and the role of specific biomarkers like Type III Procollagen Peptide (PIIINP).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to compare methotrexate prescribing and monitoring practices in Ireland with various national guidelines, including those from the European Medicines Agency (EMA), British Association of Dermatologists (BAD) and European Alliance of Associations for Rheumatology (EULAR). The goal was to document current practices among dermatologists and rheumatologists in Ireland to identify any discrepancies in methotrexate prescribing and monitoring.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;An online survey was distributed to members of the Irish Association of Dermatologists (IAD) and the Irish Society of Rheumatology (ISR) in July 2024. The questionnaire covered pretreatment screening, blood monitoring practices, folic acid supplementation and adverse events. Data was finalised and analysed in September 2024.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of the 52 respondents, all conducted baseline full blood count (FBC), renal profile (RP) and liver function tests (LFTs). Dermatologists were significantly more likely to perform infectious disease screenings compared to rheumatologists (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). When initiating methotrexate, only 17 practitioners (32.7%) employed a test dose of 2.5–5 mg weekly, with a statistically significant difference (&lt;i&gt;p&lt;/i&gt; &lt; 0.05) observed in the starting doses of methotrexate. All respondents prescribed folic acid supplementation, with a statistically significant (&lt;i&gt;p&lt;/i&gt; &lt; 0.05) noted in supplementation practices between the two specialties. Abnormal LFTs/PIIINP prompted hepatology referrals for 48%. Seven (13%) reported irreversible liver damage cases, and one (2%) death from pneumonia was noted.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study highlights significant discrepancies in methotrexate prescribing and monitoring practices among Irish clinicians, similar to the various international guidelines. These variations underscore the need for updated, unified guidelines to ensure consis","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"774-782"},"PeriodicalIF":0.5,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Dermatological Manifestations in the Intensive Care Unit of a Third-Level Hospital”","authors":"","doi":"10.1002/jvc2.70072","DOIUrl":"https://doi.org/10.1002/jvc2.70072","url":null,"abstract":"<p>S. Méndez-Flores, C. A. Mireles-Alvarez, A. Barrera-Godinez, and J. Dominguez-Cherit, “Dermatological Manifestations in the Intensive Care Unit of a Third-Level Hospital,” <i>JEADV Clinical Practice</i> 3, no. 2 (2024): 521-527, https://doi.org/10.1002/jvc2.334.</p><p>Concerns were raised by a third party regarding the high level of similarity between the abstracts of this and a previously published article [1]. The authors acknowledged their mistake, apologized for the inappropriate textual overlap and revised the wording of the abstract accordingly, as follows.</p><p><b>Abstract</b></p><p><b>Background</b>Critically ill patients frequently develop dermatological complications related to immobility, polypharmacy, and impaired tissue perfusion.</p><p><b>Objectives</b>To evaluate the prevalence, incidence, and clinical characteristics of dermatological disorders in a tertiary-level intensive care unit (ICU), and to explore their potential association with disease severity.</p><p><b>Methods</b>A prospective, observational, single-center study conducted over an 8-month period in the medical ICU of a tertiary referral hospital. Cutaneous findings were categorized as: (1) dermatologic condition as the primary reason for ICU admission; (2) pre-existing skin diseases exacerbated during hospitalization; and (3) de novo dermatologic conditions acquired during the ICU stay. Clinical severity was assessed using the APACHE II score. Non-parametric statistical tests were used for group comparisons.</p><p><b>Results</b>Among 447 patients evaluated, 105 (23.5%) presented with at least one dermatologic diagnosis, totaling 137 cutaneous conditions (ranging from 1 to 4 per patient). In 7 cases (6.7%), the skin condition was the primary reason for ICU admission; 17 patients (16.2%) had pre-existing dermatoses that worsened during their stay; and 81 patients (77.1%) developed de novo dermatoses. The most frequent diagnoses were contact dermatitis (16% of patients), skin infections (15.3%), pressure ulcers (11.7%), soft tissue edema (11%), adverse drug reactions (8.8%), cutaneous vasculitis (4.4%), and occlusive vasculopathy (4.4%). Patients with cutaneous findings had higher APACHE II scores and a greater mortality rate.</p><p><b>Conclusions</b>Dermatologic manifestations are frequent in critically ill patients and may reflect both systemic disease severity and iatrogenic complications. Most conditions developed during the ICU stay, whereas severe infections and drug-induced dermatologic reactions were notable causes of ICU admission. The presence of skin lesions correlated with greater clinical severity. Integrating dermatology into the multidisciplinary care of ICU patients facilitates the timely diagnosis and management of potentially life-threatening dermatoses, improving patient outcomes and care quality.</p><p><b>Reference</b></p><p>[1] A. Srivastava, A. D. Mathur, and S. Agarwal, “Dermatological Disorders in the Intensive Care Unit: A Descriptive Study at ","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":""},"PeriodicalIF":0.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vivo Reflectance Confocal Microscopy Findings in a Case of Syringoid Eccrine Carcinoma","authors":"J. M. Villa-Gonzalez,&nbsp;R. Gamo-Villegas,&nbsp;A. Pogorzelska-Antkowiak,&nbsp;J. Cuevas,&nbsp;S. Gonzalez","doi":"10.1002/jvc2.70038","DOIUrl":"https://doi.org/10.1002/jvc2.70038","url":null,"abstract":"<p>Herein the RCM features of syringoid eccrine carcinoma are described in a 77-year-old female patient with a facial lesion on her left cheek, emphasizing its infiltrative behaviour within a dense, sclerotic stroma. These distinctive characteristics may serve as a key diagnostic clue for syringoid eccrine carcinoma, which can clinically, dermoscopically, and even on RCM, closely resemble both benign lesions and other malignant conditions, such as basal cell carcinoma.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"862-866"},"PeriodicalIF":0.5,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists","authors":"Cathal O'Connor,&nbsp;Aoife Boyle,&nbsp;Leila Asfour,&nbsp;Bevin Bhoyrul,&nbsp;Laita Bokhari,&nbsp;George Cotsarelis,&nbsp;Chantal Cotter,&nbsp;Brittany Craiglow,&nbsp;Lara Cutlar,&nbsp;Rachita Dhurat,&nbsp;Ncoza Dlova,&nbsp;Isabella Doche,&nbsp;Jeff Donovan,&nbsp;Aaron M. Drucker,&nbsp;Samantha Eisman,&nbsp;Daniel Fernandes Melo,&nbsp;Matthew J. Harries,&nbsp;Maria Hordinsky,&nbsp;Ahmed Kazmi,&nbsp;Brett King,&nbsp;Antonios Kolios,&nbsp;Nekma Meah,&nbsp;Paradi Mirmirani,&nbsp;Arash Mostaghimi,&nbsp;Manabu Ohyama,&nbsp;Yuliya Ovcharenko,&nbsp;Rodrigo Pirmez,&nbsp;Bianca Maria Piraccini,&nbsp;Lidia Rudnicka,&nbsp;David Saceda-Corralo,&nbsp;Jerry Shapiro,&nbsp;Cathryn Sibbald,&nbsp;Rod Sinclair,&nbsp;Blake R. C. Smith,&nbsp;Michela Starace,&nbsp;Sergio Vaño-Galván,&nbsp;Wei Liang Koh,&nbsp;Katherine York,&nbsp;Ian McDonald,&nbsp;Dmitri Wall","doi":"10.1002/jvc2.70067","DOIUrl":"https://doi.org/10.1002/jvc2.70067","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Alopecia areata (AA) is a common non-scarring alopecia. Data continue to emerge on associations with autoimmune and other conditions. Janus kinase inhibitors (JAKi) are increasingly used to treat AA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim was to assess variation in laboratory testing in patients with AA among hair experts internationally and to compare subspecialized clinical practice to current guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Thirty hair experts from 14 countries and six continents contributed to develop a 24-item survey collecting demographic information on respondents; methods of severity assessment; and laboratory testing practices in AA for mimics, contributory factors, associations, and workup for systemic therapy. The survey was distributed to a global network of expert hair specialists.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 214 respondents, 79.9% (171/214) had special interest/expertise in hair loss disorders, and 35.5% (<i>n</i> = 76) were based in Europe. Most cared for both adults and children (87.9%, <i>n</i> = 188). For clinical assessment, almost two-thirds (63.6%, <i>n</i> = 136) used the Severity of Alopecia Tool and 38% (<i>n</i> = 84) used the Dermatology Life Quality Index. Only 24.3% (<i>n</i> = 52) typically tested for alternative infectious or inflammatory diagnoses, 39.7% (<i>n</i> = 85) typically tested for contributory conditions such as nutritional deficiencies, and 50.9% (<i>n</i> = 109) typically tested for co-existent autoimmune illnesses. Thyroid function testing was routinely performed in 73.4% (<i>n</i> = 157) and complete blood count (CBC) was checked in 65.9% (<i>n</i> = 141). Compared to conventional systemic therapy, experts were more likely to check lipid levels, creatine kinase, coagulation profiles, thrombophilia screens, tuberculosis blood testing, hepatitis B and C serology before prescribing JAKi.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Real world practice of laboratory testing for AA by hair experts, who may see more severe or complex alopecia, is variable. Most experts routinely perform thyroid function and CBC testing. We discuss evidence for indications for testing for AA mimics, contributory factors, associated autoimmune conditions, and before systemic therapy. Further research is required to characterise the role of laboratory testing in AA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"811-820"},"PeriodicalIF":0.5,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Understudied Landscape of Hidradenitis Suppurativa in Asian Skin of Colour Populations","authors":"Anju George","doi":"10.1002/jvc2.70065","DOIUrl":"https://doi.org/10.1002/jvc2.70065","url":null,"abstract":"&lt;p&gt;The article by Prieto et al. [&lt;span&gt;1&lt;/span&gt;] was an interesting read and brings attention to the disproportionate burden of hidradenitis suppurativa (HS) among patients with skin of colour (SOC), particularly African American and Hispanic populations. However, a significant underrepresentation of Asian population has been noted throughout the review. While the article highlights limited data on Asian populations, a PubMed and Google Scholar search reveals several regional studies from various parts of Asia that contribute valuable insights into the epidemiology and clinical presentation of HS. Though the article [&lt;span&gt;1&lt;/span&gt;] appropriately frames HS within the context of skin of colour, it is important to recognise that SOC is not a homogenous category. Asia is a highly heterogeneous region comprising numerous racial and ethnic groups, with the period prevalence of HS reported to be 0.06% [&lt;span&gt;2&lt;/span&gt;]. Asian populations—encompassing East Asia (e.g., China, Korea, Japan), Southeast Asia (e.g., Singapore, Malaysia), and South Asia (e.g., India, Pakistan, Bangladesh)—span a broad spectrum of Fitzpatrick skin types (III to VI), each with distinct epidemiological and disease patterns. Central (Kazakhstan, Uzbekistan, Turkmenistan) and Western Asia (Saudi Arabia, UAE) differ in skin phenotype (Fitzpatrick 2–4) and ethnic composition compared to the rest of Asia.&lt;/p&gt;&lt;p&gt;Among the Southeast Asian cohorts from Singapore and Malaysia, Indian patients appear disproportionately affected by HS while Chinese patients are underrepresented relative to national census data [&lt;span&gt;2&lt;/span&gt;]. A recent systematic review and meta-analysis of 30,125 patients from East and Southeast Asia highlights distinct demographic and clinical patterns, revealing a male predominance (66%), lesion distribution favoring the axilla and gluteal area, and a notably low rate of familial HS (5%) compared to Western cohorts (30%). The male predominance in Asian HS populations has been attributed, in part, to significantly higher smoking rates among Asian men, in contrast to Western cohorts where smoking prevalence is balanced between males and females [&lt;span&gt;3&lt;/span&gt;]. Lesional distribution in HS shows some overlap between East Asia and Western countries, though the commonly involved sites differ. In East Asian cohorts like Korea and Japan, gluteal involvement is more common especially among males, whereas axillary involvement dominates among females. In contrast, Southeast Asian studies from Singapore and Malaysia consistently report the axilla as the most affected site, possibly due to climatic factors like higher humidity and sweat-induced follicular occlusion [&lt;span&gt;2&lt;/span&gt;]. Only around 5% of Asian HS patients report a positive family history, compared to approximately 30% in Western populations—a difference that may be influenced by rising obesity rates in Asia unmasking sporadic cases, and the predominance of Caucasian participants in Western studies, where familial HS i","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"902-904"},"PeriodicalIF":0.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}